Linjing Zhu

机构：Beike Biotechnology (China), Jilin Medical University, Hangzhou City University, Nanjing Medical University, Nanjing University · ORCID：0009-0005-2071-9770

发表论文 30 篇 · 总被引 637 次 · h-index 9

代表论文

• AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia (2021 · Blood Cancer Journal · 被引 163)
• A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration (2021 · Cell Reports · 被引 106)
• A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo (2020 · JCI Insight · 被引 63)
• Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration (2024 · Nature Communications · 被引 22)
• Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22) (2022 · Frontiers in Immunology · 被引 17)
• A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration (2021 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 11)